ATTRACTION-2 (Kang), 2017 NCT02267343
nivolumab alone (n=330) vs. placebo (n=163)
randomized controlled trial
nivolumab
nivolumab at 3 mg/kg every 2 weeks
placebo
placebo every 2 weeks
mGC or mGEJC - L2 - all population
double blind
49 clinical sites in japan, south korea, and taiwan,
p3 / one sided and one interim analysis. No plan found
results suggest an improvement of OS and PFS but no specific statistical plan was found to validate this results.